Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres by Gennatas, S et al.
Patterns of relapse in extrapulmonary
small cell carcinoma: retrospective
analysis of outcomes from two
cancer centres
S Gennatas,1,2 J Noble,2 S Stanway,2 R Gunapala,2 R Chowdhury,3
A Wotherspoon,4 T Benepal,5 S Popat1,2
To cite: Gennatas S, Noble J,
Stanway S, et al. Patterns of
relapse in extrapulmonary
small cell carcinoma:
retrospective analysis of
outcomes from two
cancer centres. BMJ Open
2015;5:e006440.
doi:10.1136/bmjopen-2014-
006440
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006440).
Received 22 August 2014
Revised 15 December 2014
Accepted 18 December 2014
1Faculty of Medicine, National
Heart and Lung Institute,
Imperial College London,
London, UK
2Department of Medicine,
Royal Marsden Hospital,
London, UK
3Department of Medicine,
Dimbleby Cancer Centre,
Kings College London,
London, UK
4Department of
Histopathology, Royal
Marsden Hospital, London,
UK
5Department of Oncology,
St George’s Hospital,
London, UK
Correspondence to
Dr S Popat;
sanjay.popat@rmh.nhs.uk
ABSTRACT
Objectives: We conducted a retrospective review of
patients with extrapulmonary small cell carcinomas
(EPSCCs) to explore the distribution, treatments,
patterns of relapse and outcomes by primary site.
Setting: We have reviewed the outcomes of one of the
largest data sets of consecutive patients with EPSCC
identified from two major cancer centres.
Participants: Consecutive patients with a
histopathological diagnosis of EPSCC from the two
institutions were retrospectively identified.
Primary and secondary outcome measures:
Outcomes were evaluated including stage at
presentation, treatments given, sites of relapse, time to
distant relapse, progression-free survival and overall
survival (OS).
Results: From a total 159 patients, 114 received first-
line chemotherapy, 80.5% being platinum-based.
Response rate was 48%. Commonest primary sites
were genitourinary and gynaecological. 44% of patients
presented with metastatic disease. 55.9% relapsed with
liver the commonest site, whereas only 2.5%
developed brain metastases. Median OS was
13.4 months for all patients, 7.6 months and
19.5 months for those with metastatic and non-
metastatic disease, respectively. Gynaecological and
head and neck patients had significantly better OS
compared to gastrointestinal patients.
Conclusions: EPSCCs demonstrate high response
rates to chemotherapy and high rates of distant
metastases. Primary sites may influence prognosis,
and survival is optimal with a radical strategy. Brain
metastases are rare and we therefore do not
recommend prophylactic cranial irradiation.
INTRODUCTION
Neuroendocrine tumours are epithelial neo-
plasms with predominant neuroendocrine
differentiation and, while typically seen of
pulmonary origin, can arise in most organs.1
Pathological classiﬁcation is contingent on
site of origin, ranging from low-grade
carcinoid tumours to high-grade carcinomas,
and outside the lung, the WHO classiﬁcation
broadly divides them into three main grades
(1–3), with grade 3 tumours the classiﬁer for
neuroendocrine carcinomas including extra-
pulmonary small cell carcinoma.1 2
Neuroendocrine carcinomas are most com-
monly of lung origin, typiﬁed by small cell
lung cancer (SCLC),3 now representing
around 13% of all lung cancer cases.4 Most
patients have a history of smoking,5 and
around 66% of patients present with meta-
static (extensive stage) disease.3 Prognosis is
poor, with a median overall survival (OS) of
2–4 months without treatment,3 rising to
around 10 months, and a 2-year survival of
4.6% with chemotherapy.4 6 7 Brain is a
common site of metastatic disease, occurring
in over 18% of patients at presentation, and
up to 80% at 2 years.8 Patients with SCLC
with localised disease may beneﬁt from
prophylactic cranial irradiation (PCI), with a
higher progression free survival (PFS) (rela-
tive risk (RR)=0.75, 95% CI 0.65 to 0.86,
p<0.001) and OS (15.3% in the control
Strengths and limitations of this study
▪ This is a retrospective study on one of the
largest consecutive patient series reported with
extrapulmonary small cell carcinomas (EPSCC).
▪ The outcomes of this study are consistent with
data from other, smaller data sets.
▪ The study highlights significant findings on a
variety of EPSCC outcomes, including response
to chemotherapy and rate of metastatic disease,
including brain metastases, according to primary
site.
▪ Observed differences in outcomes by site are
influenced by numbers of cases of each anatom-
ical location identified, which in turn likely
reflects local referral patterns.
▪ Lack of central pathology verification.
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group vs 20.7% in the PCI group at 3 years). It also
decreases the risk of developing brain metastases
(RR=0.46, 95% CI 0.38 to 0.57, p<0.001).9 In patients
with extensive SCLC, PCI has been shown to signiﬁ-
cantly increase OS (HR 0.68; 95% CI 0.52 to 0.88) and
signiﬁcantly decrease risk of symptomatic brain metasta-
ses (from 40.4% to 14.6% at 1 year).8
Extrapulmonary small cell carcinomas (EPSCC) are rare
high-grade neuroendocrine carcinomas arising outside
the lungs, initially described in 1930.10 Since the 1970s,
various descriptions including ‘oat cell’ and ‘extrapulmon-
ary oat cell carcinoma’ have been used to describe EPSCC,
a term that ﬁrst came into use in the 1990s,11 12 to describe
all small cell carcinomas arising outside the lungs. These
account for 0.1–0.4% of all cancers and 2.5–5% of all
small cell carcinomas in the USA.13 Since being described
as a distinct entity, EPSCC has been identiﬁed from almost
every body site excluding only the central nervous system
(CNS).12 14 15 Morphology, immunohistochemistry and
ultrastructure are identical to SCLC and, while data are
limited, potentially share common molecular features with
SCLC, and also carcinomas that typically arise from each
primary site.16 Given their rarity, most data sets are either
case-reports or small patient series. These have suggested a
poor OS14 and also suggested potential differences in pat-
terns of relapse and outcome of EPSCC from differing
primary sites, with breast, genitourinary, gynaecological,
and head and neck tumours potentially more likely to
present with localised disease, whereas gastrointestinal
(GI) EPSCC is most likely metastatic.13 14 17 18 Optimal
chemotherapy is unknown due to data paucity, and
EPSCC management is largely based on the SCLC para-
digm utilising platinum-etoposide-based chemotherapy
with or without radiotherapy.11 13–15 17 19–22 Series have
been conﬂicting on incidence of brain metastases in
EPSCC, some suggesting rates potentially lower than those
in SCLC.20 23 24
We therefore aimed to retrospectively review consecu-
tive cases of patients with EPSCC seen at two cancer
centres, in order to determine the anatomical distribu-
tion at presentation, treatments, patterns of relapse and
to explore differences in outcomes by site of primary.
MATERIALS AND METHODS
Patients were identiﬁed if registered at two neighbouring
cancer centres within the South West London Cancer
Network: The Royal Marsden Hospital and St George’s
Hospital. Eligible patients were those aged ≥18, identi-
ﬁed to have a diagnosis of small cell carcinoma includ-
ing mixed subtypes (eg, adenocarcinoma/small cell
carcinoma), but excluding those known to have a lung
primary. Patients were identiﬁed from institutional path-
ology databases, electronic and paper-based patient
records. Patients were recruited if registered at each
institution up to April 2010, to allow for mature survival
data. The study was classiﬁed and approved as a Service
Evaluation at both institutions.
Data were collected in a common secured database
with anonymised identiﬁers. Data points collected
included: age, sex, gender, smoking history (never,
current, ex-, unknown), diagnosis date, histological diag-
nosis, site of primary (subgrouped into breast, gynaeco-
logical, genitourinary, upper/lower GI, head and neck,
other, unknown), performance status (at diagnosis and at
each therapy point), stage at diagnosis (metastatic/non-
metastatic, radically/non-radically treatable), chemother-
apy administered (regime, dates, best response),
radiotherapy details (site, dose, fractionation, best
response), surgery details (margin completeness),
relapse dates, sites of relapse (locoregional/distant),
treatment of relapse, date of death or last follow-up (and
disease status). Individual pathology specimens were not
centrally reviewed. Data were veriﬁed by one of the inves-
tigators (SG) in 10% of cases. No discrepancies were
identiﬁed.
Descriptive statistics were used to summarise patient
characteristics. OS was measured from date of diagnosis
until death from any cause or censored at last follow-up
date and calculated using the Kaplan–Meier method.
Multivariate Cox regression was performed to assess
inﬂuence of covariates. A forward stepwise selection
process was used to build a multivariable model for OS.
All variables with p value <0.2 signiﬁcance in the univari-
ate analysis were included in the multivariate analysis to
identify independent prognostic factors. For site of
primary cancer, the Cox regression coefﬁcients were
determined relative to the reference category (arbitrarily
deﬁned as GI patients). PFS was measured from date of
diagnosis until the ﬁrst documented progression in any
site following initial treatment or until death from any
cause or censored at last follow-up date. Time to distant
relapse (TTDR) was measured from date of last treat-
ment received until date of ﬁrst relapse or else censored
at the date of last follow-up.
RESULTS
Between 05/05/1978 and 08/04/2010 data for 166
patients with a diagnosis of EPSCC were recorded
between the two institutions. However, ﬁve patients were
duplicates (due to hospital transfer) and two patients
were less than 18 years old at diagnosis. Hence, only 159
patients were assessed for analysis. Mean age at diagnosis
was 61 years ranging from 19 to 90, with 70 males and
89 females (male: female ratio 1:1.3). Performance
status at diagnosis was poorly documented (unknown for
75% of cases) as was weight loss (unknown for 72% of
cases) and was, therefore, not included in analysis.
Although smoking status was unknown for 48% of cases,
in those with known status, only 13% and 58% of
patients were current or ex-smokers at time of diagnosis,
respectively.
The majority of cases were reported as pure EPSCC
(123 cases, 77.4%), while the remainder were admixed
with other histological subtypes, including EPSCC/
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adenocarcinoma (18, 11.3%), EPSCC/transitional cell
carcinoma (12, 7.5%), EPSCC/squamous cell carcinoma
(5, 3.1%) and EPSCC/other (1, 0.6%).
One hundred fourteen patients received chemother-
apy alone or in combination with radiotherapy as ﬁrst-
line treatment. Response assessment data were available
in 113 patients (71.1%). Of those, 25 (22.1%) were
non-evaluable. In the 88 remaining patients, complete
remission was observed in 6 patients (6.8%), partial
remission in 49 (55.7%) (Overall response rate was
62.5% in the 88 patients and 48% in all 114 patients),
stable disease rate in 14 (15.9%) and progression
observed in 19 (21.6%).
Of the 113 patients who received chemotherapy, 91
(80.5%) received platinum-based chemotherapy (carbo-
platin or cisplatin), either alone or in combination. The
commonest combination was carboplatin/etoposide
doublet (37 patients, 32.8% of all patients who received
chemotherapy). In total, 71 patients (62.8%) received
combination chemotherapy containing etoposide. In 54
cases it was administered as part of a platinum-based
doublet or triplet and in 16 as part of ACE (doxorubi-
cin, cyclophosphamide, etoposide), which was the com-
monest non-platinum containing regimen. 65 of the 113
patients, who received chemotherapy, relapsed (57.5%).
Of those, 28 (43.1%) received second-line chemother-
apy. Of the 13 regimens given, the commonest was
ACE (6 cases, 21.4%). Ten patients (35.7%) received
platinum-containing regimens and 10 (35.7%)
etoposide-containing regimens. Seventeen of the 28
patients had a second relapse (60.7%). Four (23.5%)
received third-line chemotherapy and all relapsed for a
third time. One received fourth-line chemotherapy.
Primary sites of disease were grouped by organ system
to aid analysis (table 1). The commonest primary sites
were genitourinary (n=51, 32.1%) and gynaecological
(n=49, 30.8%), followed by upper GI (n=29, 18.2%),
and head and neck (n=14, 8.8%). Primary EPSCCs of
the breast and CNS were the rarest. At diagnosis, 70
patients presented with metastatic disease and 87 with
non-metastatic disease, accounting for 44.0% and 54.7%
of patients, respectively. For two patients this information
was unavailable (1.3%). Only one patient was recorded
as having had brain metastases at presentation (0.6%).
This was from a pancreatic primary site.
Of the 159 patients, 74 (46.5%) were treated with a
radical intent, 83 (52.2%) palliative intent and for
2 (1.3%) this information was unavailable. Fifty one
(32.1%) patients received chemotherapy only, 17
(10.7%) radiotherapy only and 15 (9.4%) had surgery
only. Chemoradiotherapy was given in 30 cases (32.1%)
and surgery with preoperative or postoperative chemo-
therapy in 34 (21.4%). Treatment details were unavail-
able for 12 (7.5%).
Of the total 159 patients 89 relapsed (55.9%). Twenty
two patients (13.8%) had local recurrence at ﬁrst relapse,
47 (29.6%) distant metastases only and 20 (12.6%) had
both local and distant disease. Thirty eight patients
(23.9%) progressed on ﬁrst-line treatment and died
shortly after. The commonest site for metastatic disease
was the liver (18 of 89 patients, 20.2%). Only four patients
had brain metastases at time of ﬁrst relapse (two brain
only and two extracranial and intracranial disease), repre-
senting 2.5% of all patients. There was no documentation
of these patients having been symptomatic. Nineteen
patients were excluded from TTDR analysis due to lack of
accurate documentation of timing or sites of disease at
relapse. From the remaining 140 patients assessed, median
follow-up time for all patients was 5.8 months (range:
4 days–10.7 years). Sixty seven patients relapsed and 73
were censored. Median TTDR was 12.2 months (95% CI
1.9 to 22.5 months). For the ﬁrst 5 years following treat-
ment the survival percentage was 50.7%, 38.3%, 34.6%,
32.3% and 29.4%, respectively. The percentage then plat-
eaued and remained unchanged to 10 years.
PFS analysis was performed on all 159 patients. One
hundred and twenty seven patients progressed or died
and 32 were censored. Median PFS for all patients was
8.4 months (95% CI 6.7 to 10.2 months) (ﬁgure 1). OS
analysis was performed on all 159 patients. One hundred
and fourteen patients died and 45 were censored.
Median OS for all, non-metastatic and metastatic patients
was 13.4 months (95% CI 10.8 to 16.0), 19.5 months
(95% CI 9.3 to 29.7) and 7.6 months (95% CI 5.0 to
10.2), respectively (ﬁgure 2A, grouped by disease stage).
When analysed for treatment intent, patients treated with
Table 1 Primary sites of extrapulmonary small cell
carcinomas identified
Site of primary cancer
Frequency (%)
[Contributing cases]
Breast 3 (1.9)
Lower gastrointestinal 7 (4.4)
Bowel 7
Upper gastrointestinal 29 (18.2)
Liver [4]
Oesophagus [16]
Pancreas [7]
Stomach [1]
Small bowel [1]
Genitourinary 51 (32.1)
Bladder [30]
Prostate [17]
Other [4]
Gynaecological 49 (30.8)
Cervix [20]
Endometrium [6]
Ovary [19]
Other [4]
Head and neck 14 (8.8)
Pharynx [1]
Parotid [1]
Salivary gland [3]
Other [9]
Unknown primary 6 (3.8)
Lymph nodes only [6]
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palliative (‘non-radically treatable’) versus radical intent
had a poorer OS of 8.8 months (95% CI 6.5 to 11.0) com-
pared to 25.6 months (95% CI 4.1 to 47.1), respectively
(ﬁgure 2B). All variables in the univariate analysis were
signiﬁcantly associated with survival. OS for gynaeco-
logical, and head and neck patients, was signiﬁcantly
longer compared to GI patients, while for other tumour
types despite a suggestion thereof, this was not signiﬁcant
(table 2). However, in the multivariate analysis only treat-
ment received and metastatic stage were signiﬁcant in the
ﬁnal model (table 3). As the core strategies for the treat-
ment of high-grade neuroendocrine tumours have
remained relatively consistent throughout the years and
given the size of our data set, we did not perform differ-
ential time-to-event analysis.
DISCUSSION
We have reviewed the outcomes of one of the largest
retrospective data sets of consecutive patients with
EPSCC identiﬁed from two cancer centres. Our data
have conﬁrmed that EPSCC is a highly aggressive carcin-
oma with a poor prognosis for metastatic disease,
although substantially improved for those treated radic-
ally. We conﬁrm the common anatomical sites of
primary and suggest differences in outcome from differ-
ing primary site. We conﬁrm a high rate of relapse to
distant sites, especially the liver and identify that this
occurs early, suggesting a CT-based surveillance strategy
might be of beneﬁt in order to identify early asymptom-
atic relapsed disease. Moreover, we have documented
that, unlike SCLC where up to 40.4% patients with
extensive disease develop brain metastases at 1 year in
the absence of PCI,8 brain metastases in EPSCC are rare
(2.5% in our study) at presentation and on follow-up.
This is consistent with other retrospective data sets that
have reported incidence of 4–13%,13 18 20 24 including a
registry series (6.4% incidence23). Other differences
compared to those typically observed in SCLC include a
male:female ratio of 1:1.3. (compared to SCLC, 1.7:112)
and a low recorded smoking history, consistent with that
from other EPSCC series, with proportions of smokers
ranging from 19% current and 32% ex-smokers13 to
30% current smokers.23
Data on outcomes and natural history of EPSCC have
been limited given its rarity, and generally based on
smaller retrospective case series to date (table 4),
barring two registry series, one from South East
England12 and one from Ireland.23 Our data set is one
of the largest consecutive patient series reported, and
presents outcomes consistent with other data sets.
Speciﬁcally, the commonest primary sites of disease in
our study were genitourinary and gynaecological, fol-
lowed by upper GI, and head and neck. Other studies
have shown very similar ﬁndings,12–15 18 23 25 with the
exception of Wong et al,12 where breast was the primary
site in 10% of cases. In agreement with previous studies
primary site of disease is associated with OS. From previ-
ous data sets, patients with GI primaries have the worst
Figure 1 Kaplan–Meier plot for progression-free survival for
all patients.
Figure 2 (A) Kaplan–Meier plot for overall survival (OS) for
all patients, grouped by disease stage at diagnosis.
(B) Kaplan–Meier plot for OS for all patients, grouped by
treatment intent.
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prognosis,11 12 17 with breast and genitourinary sites
reporting improved survival.11 12 14 22 25 These ﬁndings
can be in part explained by the disease stage at diagno-
sis.13 14 17 18 In our study, although site was a signiﬁcant
covariate of survival, likely due to limited numbers of
patients, genitourinary, and head and neck patients had
signiﬁcantly better survival compared to GI patients.
These differences in outcomes change by site in our
report and are inﬂuenced by numbers of cases of each
anatomical location identiﬁed, which in turn likely
reﬂects local referral patterns.
Median OS in this study was 13.4, 7.6 and 19.5 months
for all, metastatic and non-metastatic patients, respect-
ively, again relatively consistent with previous studies
identifying an OS of 9.8–14 months, 2–9.2 months and
16.8–34 months for all, extensive-stage and limited-stage
patients, respectively (table 4).11–14 20 21 Wong et al12
reported an overall 3-year survival of 30% for patients
presenting with limited disease and 10% for those with
extensive disease, comparable to the 34.6% survival for
all patients at 3 years in this study.
In the multivariate analysis only treatment intent and
stage were signiﬁcant covariates, again consistent with
existing data sets.19 20 Other studies have found a higher
white cell count at diagnosis,14 poor performance status,
weight loss prior to diagnosis, omission of radical radio-
therapy11 13 14 24 and male gender25 to be signiﬁcantly
associated with a poor OS. A better outcome for female
patients could in part be attributed to the early stage at
diagnosis of gynaecological EPSCC.14 25 The same
factors are important in regard to PFS, which has been
reported as 13.5–20 months in limited and 3–12 months
in extensive disease in other studies.14 20
The studies included in this table are not the result of
a systematic review. These are the largest studies on
EPSCC with OS data on patients with LS and ES.
Table 3 Multivariate Cox regression model for overall survival
Variables HR 95% CI p Value
Stage
Non-metastatic 1
Metastatic 2.4 1.5 to 3.8 <0.001
Treatment received (prior to progression)
No treatment received (reference) 1
Chemotherapy 0.06 0.02 to 0.13 <0.001
Radiotherapy 0.09 0.03 to 0.23 <0.001
Surgery 0.03 0.01 to 0.08 <0.001
Combination chemoradiotherapy 0.04 0.02 to 0.10 <0.001
Combination chemosurgery 0.02 0.01 to 0.06 <0.001
Variable overall <0.001
Table 2 Univariate Cox regression analysis for overall survival
Variables HR 95% CI p Value
Stage
Non-metastatic 1
Metastatic 3.2 2.1 to 4.7 <0.001
Treatment intent
Non-radically treatable intent 1
Radically treatable intent 0.3 0.2 to 0.5 <0.001
Site of primary
Lower/upper gastrointestinal 1
Genitourinary 0.7 0.4 to 1.2 0.177
Gynaecological 0.6 0.3 to 0.9 0.027
Head and neck 0.3 0.2 to 0.8 0.008
Breast 0.3 0.04 to 2.1 0.218
Variable overall 0.030
Treatment received (prior to progression)
No treatment received (reference) 1
Chemotherapy 0.05 0.02 to 0.12 <0.001
Radiotherapy 0.05 0.02 to 0.14 <0.001
Surgery 0.02 0.01 to 0.05 <0.001
Combination chemoradiotherapy 0.03 0.01 to 0.07 <0.001
Combination chemosurgery 0.02 0.01 to 0.04 <0.001
Variable overall <0.001
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While a number of biases may have inﬂuenced our
results given the retrospective nature of this study and
lack of central pathology veriﬁcation, our data support
those identiﬁed from other, smaller data sets. We have
shown that while similar to SCLC in terms of high
response rates to platinum-etoposide-based chemother-
apy, and high rates of distant metastases (especially to
the liver), there are notable differences to ESPCC. Here,
incidence in smokers is lower than SCLC and may
potentially reﬂect differing pathobiology. Moreover, the
brain remains an uncommon site of metastases and we
therefore do not recommend PCL. Finally, the site of
primary may inﬂuence prognosis, and survival is optimal
with a radical strategy. ESPCC remains a rare diagnosis,
and concerted efforts into better understanding the bio-
logical mechanisms that underpin its pathogenesis and
relationship to SCLC pathobiology is urgently warranted
in order to improve clinical outcomes.
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